Summary

Hester Biosciences has announced its unaudited financial results for Q2 & H1 FY26. The standalone performance shows a decline in divisional product sales and profit, while the consolidated performance shows an increase in divisional product sales and profit. The Poultry Healthcare Division reported growth, while the Animal Healthcare Division faced delays in government-led immunisation programmes.

Key Highlights

1. 1

   Standalone Performance Down: Divisional Product Sales down by 12% in Q2 FY26 and 13% in H1 FY26, Profit down by 23% in Q2 FY26 and 15% in H1 FY26

2. 2

   Consolidated Performance Up: Divisional Product Sales up by 71% in Q2 FY26 and 99% in H1 FY26, Profit up by 7% in Q2 FY26 and 9% in H1 FY26

3. 3

   Poultry Healthcare Division reported 18% growth in Q2 FY26 and 10% growth in H1 FY26

4. 4

   Animal Healthcare Division faced delays in government-led immunisation programmes, accounting for a significant portion of institutional demand

5. 5

   Hester received market authorisation for the HIN2 vaccine, strengthening its poultry vaccine portfolio

6. 6

   Hester Nepal recorded a net loss in Q2 FY26, but expects execution of pending institutional orders to accelerate in the second half of the year